

Small Molecules of the Month



NVL-520 ROS1

oral brain-penetrant ROS1-selective TKI Ph. I/II for NSCLC and other solid tumors rationally designed (SBDD) from known starting point *Press Release*, September 2023 NUVALENT INC., CAMBRIDGE, MA



GDC-1971 (RLY-1971) SHP2


oral allosteric SHP2 inhibitor

Ph. I for advanced or metastatic solid tumors

virtual screening with MD simulation based on known matter


J. Med. Chem., September 2023

RELAY THERAPEUTICS, MA / GENENTECH, CA



encaleret

CaSR oral CaSR antagonist (calcilytic) Ph. III for ADH1 opt. from known starting point from HTS *N. Engl. J. Med.*, September 2023 JAPAN TOBACCO, JP / CALCILYTIX, CA




mezigdomide

oral cereblon-based IKZF1/3 degrader

Ph. III for relapsed and refractory multiple myeloma


phenotypic and protein degradation screen vs. IKZF1 and 3

N. Engl. J. Med., September 2023 CELGENE CORPORATION, SAN DIEGO, CA




BMS-986172

MGAT2 oral MGAT2 inhibitor Ph. I for obesity from opt. of previous clinical candidate (HTS on human MGAT2) J. Med. Chem., September 2023 BRISTOL MYERS SOUIBB COMPANY, NJ




dalcetrapib

CETP inhibitor thioester prodrug Ph. III for cardiovascular diseases repurposed HDL cholesterol modulator *Press Release*, September 2023 JAPAN TOBACCO, JP / DALCOR, CA



mavorixafor

CXCR4 oral allosteric CXCR4 inhibitor Ph. III NDA for WHIM syndrome opt. from plerixafor *Press Release*, September 2023 X4 PHARMACEUTICALS, BOSTON, MA



tovorafenib (BIIB-024) RAF

oral CNS-penetrant selective type II pan-RAF inhibitor

Ph. III for pediatric low-grade glioma (LGG) activity for LGG identified in cell-based

screening of RAF inhibitors


Press Release, September 2023 BIOGEN / TAKEDA / DAY ONE

$\begin{array}{c} - & & \\ + & & \\ + & & \\ + & & \\ + & & \\ + & & \\ + & & \\ + & & \\ - & & \\ + & & \\ - & & \\ + & & \\ - & & \\ + & & \\ - & &$

AZD4604

JAK1 inhalable JAK-1 selective inhibitor Ph. II for asthma opt. from oral JAK1 program (HTS of AstraZeneca collection vs. JAK1) *J. Med. Chem.*, September 2023

ASTRAZENECA, GOTHENBURG, SE



ABX-002

TR-βselective CNS-penetrant TR-β agonist prodrugPh. Il for major depressive disorder (MDD)CNS-penetrant prodrug from known TR-βagonist chemotypePress Release, September 2023

AUTOBAHN THERAPEUTICS, SAN DIEGO, CA



HIGHLIGHTS FROM DRUG DISCOVERY ARTICLES PUBLISHED ONLINE | SEPTEMBER 2023